Antiviral drug discovery: preparing for the next pandemic
Catherine S. AdamsonBiomedical Sciences Research ComplexKelly ChibaleDepartment of Chemistry and Institute of Infectious Disease and Molecular MedicineRebecca J. M. GossNorth HaughMarcel JasparsDepartment of ChemistryDavid NewmanFrederick National LaboratoryRosemary A. DorringtonDept. of Biochemistry and Microbiology
2021en
ABI
Аннотация
Clinically approved antiviral drugs are currently available for only 10 of the more than 220 viruses known to infect humans. The SARS-CoV-2 outbreak has exposed the critical need for compounds that can be rapidly mobilised for the treatment of re-emerging or emerging viral diseases, while vaccine development is underway. We review the current status of antiviral therapies focusing on RNA viruses, highlighting strategies for antiviral drug discovery and discuss the challenges, solutions and options to accelerate drug discovery efforts.
Перевод пока недоступен
Идентификаторы
Цитирования и источники
Цитирований: 2Использованных источников: 0